FindTrial
Sign In

Add-on, open-label, phase III study of CS-866AZ

Add-on, open-label, phase III study of CS-866AZ

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220290
Enrollment
Unknown
Registered
2006-08-10
Start date
2006-08-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

investigational material(s) Generic name etc : CS-866AZ (olmesartan medoxomil / azelnidipine) INN of investigational material : olmesartan medoxomil/azelnidipine Therapeutic category code : 214 Antihy

Sponsors

DAIICHISANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient with essential hypertension not adequately controlled by CS-866 and CS-905 monotherapy, aged 20 years or older

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026